worldwide 1,2) with annual volumes of approximately 160000 isolated cases in the US. 3) There is a significant inter-country variation with recent incidence rates ranging from 17 to 73 per 100000 inhabitants in western European countries. 4) The absolute number of CABG has fallen during the last decade due to an increase in percutaneous coronary intervention (PCI) procedures. For example, in Germany, between 2008 and 2018, isolated CABG surgery decreased from 47337 to 33999 cases (-28%). According to current international guidelines, in single-vessel disease, low-risk multi-vessel coronary artery disease or isolated left main disease PCI is generally preferred; on the other hand, CABG is usually recommended in patients with complex two-vessel disease, three-vessel disease, and/or non-isolated left main disease. 5) Bilateral internal mammary artery (BIMA) in coronary artery bypass grafting (CABG) has traditionally been limited. This review looks at the recent outcome data on BIMA in CABG focusing on the management of risk factors for mediastinitis, one of the potential barriers for more extensive BIMA utilization. A combination of pre-, intra-and postoperative strategies are essential to reduce mediastinitis. Limited data indicate that the incidence of mediastinitis can be reduced using closed incision negative-pressure wound therapy as a part of these strategies with the possibility of offering patients best treatment options by extending BIMA to those with a higher risk of mediastinitis. Recent economic data imply that the technology may challenge the current low uptake of BIMA by reducing the short-term cost differentials between single internal mammary artery and BIMA. Given that most published randomized controlled trials and meta-analyses of observational long-term outcome data favor BIMA, if short-term complications of BIMA including mediastinitis can be controlled adequately, there may be opportunities for more extensive use of BIMA leading to improved long-term outcomes. An ongoing study looking at BIMA in high-risk patients may provide evidence to support the hypothesis that mediastinitis should not be a factor in limiting the use of BIMA in CABG.